TherapeuticsMD (NASDAQ:TXMD) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report released on Thursday morning. The firm issued a hold rating on the stock.

TherapeuticsMD Stock Performance

TXMD stock opened at $1.37 on Thursday. The business has a fifty day simple moving average of $1.56 and a 200-day simple moving average of $1.76. TherapeuticsMD has a 52 week low of $1.15 and a 52 week high of $2.99.

Hedge Funds Weigh In On TherapeuticsMD

An institutional investor recently raised its position in TherapeuticsMD stock. Clearline Capital LP increased its holdings in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 636,622 shares of the company’s stock after acquiring an additional 101,282 shares during the quarter. Clearline Capital LP owned approximately 5.52% of TherapeuticsMD worth $1,025,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 30.74% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.